Aktiespot

Hanall Biopharma Co., Ltd. (HANALL BIOPHARMA) aksje

009420.KS

Stengt
₩57,900.00+2,500.00 (+4.51%)
Laster graf...
HANALL BIOPHARMA logo

HANALL BIOPHARMA

Åpning58,300.00
Høy61,000.00
Lav55,500.00
Volum675.97k
P/EN/A
Markedsverdi2.94T
52-ukers høy73,000.00
52-ukers lav24,000.00
Gj.sn. volum488.77k
UtbytteN/A
Beta0.79
EPSN/A

Om Hanall Biopharma Co., Ltd. (HANALL BIOPHARMA) aksje

Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.

Selskapsinformasjon

Børs: KSE (KSC)
Sektor: Sundhed
Industri: Lægemiddelproducenter – Special og generisk
Adresse:
43, Sangseodang 1-gil
Daejeon, South Korea
Telefon: + 82 42 932 5997

Analytikernes aksjeanbefalinger

Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.

Anbefaling:1.40 - Stærk køb
Laveste kursmål
70,000.00
20.9%
Gjennomsnittlig kursmål
82,000.00
41.6%
Median kursmål
76,000.00
31.3%
Høyeste kursmål
100,000.00
72.7%

Andre ser også på: